Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study

Abstract

it is crucial to ensure good quality, understandability and reliability prior to publication. Patients should be advised to critically evaluate the source and content of a video and not to simply trust the number of likes. Health care providers and authorities should take joint measures to implement quality control of videos on YouTube TM. The results of our study may encourage shared decision-making and be beneficial for both patients and health care providers to recommend appropriate videos to their patients. We thank Heike Weingarten and Cindy G€ orgmayr for their valuable support in evaluating the 49 videos. Funding: None.

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

“…It is important to highlight that patients in our real-life study had a baseline PASI of 20 ± 13.3 vs. 12.7 ± 8.95 and 13.7 ± 7.7 in the French and Spanish study, respectively, and the level of improvement attained was consistent at these early time points and maintained up to 1 year. Together, real-life experience using guselkumab in Spain [ 27 ], France [ 28 ], and findings reported here in Italy, confirm the early, rapid, and sustained effectiveness of guselkumab. Findings from these real-life studies confirm data derived from VOYAGE 1 and 2 [ 7 , 8 ], despite differences in patient characteristics such as disease severity at baseline, exposure to PBTs, and gender, already noted [ 28 ].…”

“…The efficacy of guselkumab treatment was also recently evaluated in two real-life studies [ 27 , 28 ]. In the first study performed in Spain, 55 patients with moderate-to-severe plaque-type psoriasis were treated with guselkumab over a period of 36 weeks [ 27 ].…”

“…However, the greater efficacy observed at later time points for PASI 90 and PASI 100 response may be attributed to higher baseline PASI in our study (20 vs. 13.7) as previously shown in the real-life BioCAPTURE cohort, where a baseline PASI ≥10 was found to be a strong predictor for achieving PASI 90 [ 29 ]. In the second study, undertaken in France, the effectiveness and tolerance of guselkumab for psoriasis under real-life conditions was also evaluated in a multi-center study up to 16 weeks [ 28 ]. Overall, 38.3% of patients achieved PASI 100 at week 16 and 50.6% achieved PASI 90.…”

“…Lack of effectiveness in obese patients may be attributed to lower blood drug levels as well as higher body surface area or increased levels of adipose tissue-derived pro-inflammatory cytokines [ 33 , 34 ]. Considering that over one-third of patients with moderate-to-severe psoriasis can also be obese [ 16 , 35 , 36 ], and also in real-life clinical practice [ 27 , 28 ], the availability of biologics such as guselkumab undoubtedly offer significant benefit in these severe patients over several other biologics.…”

Real‐life experience of guselkumab in patients with psoriasis

“…At week 16, 51% of patients achieved PASI 90 response, lower than that observed in the RCTs; however, a similar proportion (38%) of patients achieved PASI 100 response. 8 These disparities between real-life studies and RCTs highlight the importance of daily practice results when assessing a new agent.…”